B2i Digital

Spartan Capital Securities, LLC and B2i Digital are pleased to announce that Lucosky Brookman LLP is the Headline Sponsor of the upcoming Spartan Capital Investor Conference on November 3rd, 2025, in New York. The Spartan Capital Investor Conference 2025 is a B2i Digital Featured Conference. See more information at https://lnkd.in/edsVSMsh. Now in its second year, the Spartan Capital Investor Conference brings together public company executive teams, institutional investors, and thought leaders from across the U.S. capital markets for strategic networking and information exchange. Taking place on November 3rd, 2025, at the Marriott Marquis Hotel in New York, this premier event will welcome more than 500 institutional and high-net-worth investors and feature presentations from 60 public and private growth companies across technology, healthcare, consumer, and other high-opportunity sectors. Attendees can expect main-stage presentations, curated one-on-one meetings, and extensive networking opportunities that connect innovative companies with sophisticated capital. Lucosky Brookman is a corporate and litigation law firm headquartered in the New York metropolitan area with offices and attorneys across the country, representing both domestic and international clients in sophisticated corporate and securities transactions, mergers and acquisitions, secured and unsecured lending transactions, PIPEs, general corporate matters, complex commercial litigation, securities litigation, white collar and regulatory matters, and insurance coverage and defense matters. The firm is led by Founding and Managing Partner Joseph Lucosky and Founding Partner Seth Brookman, who serves as Administrative Partner and Head of Banking and Finance, supported by a team of over 70 attorneys nationwide. Event details and registration are available at https://lnkd.in/edsVSMsh. B2i Digital is working closely with the outstanding Spartan Capital team, including John D. Lowry (CEO), Kim Monchik (CAO), Stephen Faucetta (Managing Director), and Julia Voss (Executive Assistant), to deliver an exceptional conference experience. Investors can register to attend: https://lnkd.in/g8Y249nF.

Kolibri Global Energy Inc. (Nasdaq: KGEI, TSX: KEI) announced that the Toronto Stock Exchange has approved its normal course issuer bid to repurchase up to 1,768,841 common shares, representing approximately 5% of outstanding shares. Kolibri Global Energy is a B2i Digital Featured Company. View their complete profile at https://lnkd.in/eVHcxRGp and follow Kolibri on X, Facebook, and LinkedIn. • The share buyback program will run for one year from September 23, 2025 to September 22, 2026 • Shares may be purchased on the TSX, Nasdaq, or alternative Canadian trading platforms at prevailing market prices • Daily purchase limits: greater of 1,000 shares or 25% of average daily trading volume (10,626 shares on TSX based on recent volumes); on Nasdaq, up to 25% of average daily trading volume during the prior four weeks, subject to block purchase exceptions • All repurchased shares will be cancelled and funded from working capital; purchases will only be made with cash distributed by Kolibri Energy US Inc. in compliance with its credit facility • The Board believes Kolibri’s share price does not fully reflect the company’s underlying value and considers the program an appropriate use of funds • Under the prior buyback program, Kolibri purchased 548,293 shares at a weighted average price of CAD$7.21 per share The complete news release is available at https://lnkd.in/e-Ysw99a. Kolibri is led by Wolf Regener, President and CEO, alongside a seasoned technical team including CFO Gary Johnson, CPA, MBA, Director of Engineering Dan Simpson, Senior Geologist Allan Hemmy, and Landman Dalia Lupita Isaac. The company is focused on developing its oil-rich Caney acreage in Oklahoma. For additional details, please visit the Investors section of Kolibri’s website at: https://lnkd.in/eWPQ-Xz6. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted KGEI stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of KGEI or any security, and it is not intended to offer any opinion on KGEI as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m.

OS Therapies (NYSE American: OSTX) announced that it has been invited to participate in the “Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics” Spotlight Panel at BioFuture 2025 on October 13, 2025 at 11:00am EDT at Cure in New York City. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/epFNRZQB. As noted in the release: • The Company will provide an overview with emphasis on clinical development and commercial plans for OST-HER2, its lead immunotherapy candidate for osteosarcoma • OST-HER2 has received FDA Rare Pediatric Disease Designation, Fast-Track designation, and Orphan Drug designations from both FDA and EMA • The Company reported positive Phase 2b data demonstrating statistically significant benefit in 12-month event-free survival for recurrent, fully resected, lung metastatic osteosarcoma • OS Therapies is positioned to commence BLA submission to the FDA in Q4 2025 and, if approved prior to September 30, 2026, would receive a Priority Review Voucher (PRV) that it intends to sell • OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients and received conditional USDA approval for treating canine osteosarcoma • PRV proceeds would fund further development of OST-HER2 into other osteosarcoma indications and into breast cancer and other HER2-positive cancers, and would also be used to advance pipeline candidates including OST-504 (prostate cancer) and OST-503 (NSCLC and other solid tumors) • Virtual partnering option available October 21-23, 2025, including access to recorded content Paul Romness, MPH, Chairman & CEO of OS Therapies, stated, “BioFuture 2025 is one of the premier meetings in the biotechnology sector, and we are honored to be invited to participate in the Cancer spotlight panel. The story of how OS Therapies has leveraged over $300 million in invested capital into our listeria monocytogenes platform technology (the “Listeria Platform”) to potentially bring the first new treatment to market for osteosarcoma in over 40 years is compelling. See the full release at https://lnkd.in/e2bSYQCz Led by CEO Paul Romness and an experienced executive team that includes Chris Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), Jack Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on advancing its pipeline for osteosarcoma and other hard-to-treat cancers. Learn more about OS Therapies’ work at https://lnkd.in/eaAJSfqz and visit B2i Digital for updates. For investor-related questions, please see OS Therapies’ Investor Relations page or email OSTX@waterseid.com.

YY Group Holding (Nasdaq: YYGH) announced preliminary, unaudited results for the first half of 2025. The company plans to provide full first-half results by the end of September. YY Group recently debuted as the newest B2i Digital Featured Company. A full investor profile is coming soon at https://lnkd.in/d3m_BMKB. Among the highlights from today’s news are: - Preliminary H1 2025 revenue of $29.4 million, up 53% year over year; gross profit of $4.6 million, up nearly 100%; gross margin expansion to 15.5% from 12.3%. - Broad-based momentum across hospitality and F&B, with increasing traction in logistics and condominium management. - Both core businesses contributed: YY Circle (on-demand staffing) and the Integrated Facility Management (IFM) platform. - Management stated they expect to exceed $60 million in full-year 2025 revenue. - Recent actions supporting growth include the addition of Property Facility Service (PFS) to enhance condominium management capabilities and qualified lead generation from subsidiary MediaPlus. Read the full press release here: https://lnkd.in/e3FGTgTe. YY Group is led by a highly experienced management team including Mike Fu , Founder & CEO; Zhang Fan, Co-Founder & Director; Phua Zhi Yong (“Jason”), CFO; Rachel Xu, CHRO; and Teng Sin Ken, CIO. To learn more about YY Group Holding Limited, visit https://lnkd.in/eJ7tfezs. For investor inquiries, contact enquiries@yygroupholding.com or visit https://lnkd.in/e3kBiyXG.

Kolibri Global Energy Inc. (Nasdaq: KGEI, TSX: KEI) announced updates on investor conference participation and its share buyback program. Kolibri Global Energy Inc. is a B2i Digital Featured Company. View their complete profile at https://lnkd.in/eVHcxRGp and follow Kolibri on X, Facebook, and LinkedIn. The company will participate in two upcoming investor conferences: the Sidoti September Virtual Investor Conference on September 17-18 (presenting at 3:15 PM ET on September 18) and the Lytham Partners Fall 2025 Conference on September 30 (presenting at 12:30 PM ET). CEO Wolf Regener will present at both conferences and host one-on-one meetings with investors at the Sidoti Conference. CFO Gary Johnson and Mr. Regener will also have virtual one-on-one meetings with investors throughout the Lytham Partners event on September 30. Additionally, Kolibri has repurchased 267,637 shares at an average price of US$6.38 in 2025, with 548,293 total shares repurchased at an average price of US$5.27 since the buyback program began. The company intends to renew the program for another year, pending regulatory approvals. The complete news release is available at https://lnkd.in/etv5Vjxe. Kolibri is led by Wolf Regener, President and CEO, alongside a seasoned technical team including CFO Gary Johnson, CPA, MBA, Director of Engineering Dan Simpson, Senior Geologist Allan Hemmy, and Landman Dalia Isaac. The company is focused on developing its oil-rich Caney acreage in Oklahoma. For additional details, please visit the Investors section of Kolibri’s website at: https://lnkd.in/eWPQ-Xz6. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted KGEI stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of KGEI or any security, and it is not intended to offer any opinion on KGEI as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m.

Spartan Capital Securities and B2i Digital are pleased to announce that Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) will be a presenting company at the upcoming Spartan Capital Securities, LLC Investor Conference on November 3rd, 2025, in New York. The Spartan Capital Investor Conference 2025 is a B2i Digital Featured Conference. Now in its second year, the conference brings together public company executive teams, institutional investors, and thought leaders from across the U.S. capital markets for strategic networking and information exchange. Taking place at the Marriott Marquis Hotel in New York, this premier event will welcome 500+ institutional and high-net-worth investors and feature presentations from 60 public and private growth companies across technology, healthcare, consumer, and other high-opportunity sectors. Attendees can expect main-stage presentations, curated one-on-one meetings, and extensive networking opportunities that connect innovative companies with sophisticated capital. Investors can register to attend: https://lnkd.in/g8Y249nF. Event details and registration are available at https://lnkd.in/edsVSMsh. Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing a new class of oncology treatments and cancer therapies called PP2A inhibitors. In recent years, the field of cancer treatment has undergone remarkable advancement with the introduction of immunotherapy. This approach has revolutionized the landscape of cancer care. Both chemotherapy, and immunotherapy are treatment modalities that offer broad applicability to many types and stages of cancer, with the potential to benefit a wide range of patients. Our lead molecule LB-100 has shown remarkable synergy with chemotherapy and immunotherapy in a range of pre-clinical models. The company is led by CEO Geordan Pursglove, an accomplished executive with 10+ years in M&A and capital markets; CSO Bastiaan (Bas) van der Baan, a biotechnology executive with 20+ years in precision oncology; CFO Peter Stazzone, a seasoned finance professional and CPA with 25 years of expertise; and supported by a Scientific Advisory Committee including Prof. Rene Bernards, Stephen Forman MD, and Yun Yen MD PhD FACP. B2i Digital is working closely with the Spartan Capital team, including John D. Lowry (CEO), Kim Monchik (CAO), Stephen Faucetta (Managing Director), and Julia Voss (Executive Assistant), to enhance each presenter’s reach through in-depth digital profiles and targeted outreach. Learn more about Lixte Biotechnology Holdings, Inc. at https://ir.lixte.com/

YY Group Holding Limited (Nasdaq: YYGH) announced that it has signed a non-binding Memorandum of Understanding (MOU) with UnoMove (Younuozhixing Technology Co., Ltd.), a Suzhou-based innovator in autonomous robotics, to collaborate on developing and commercializing autonomous facade cleaning drone technology. YY Group is a B2i Digital Featured Company. A full investor profile is coming soon at https://lnkd.in/d3m_BMKB. Among the highlights from the news release include: • The partnership focuses on developing and commercializing UnoMove’s facade cleaning drone, a next-generation solution designed to address one of the most hazardous tasks in facility management • Upon launch, YY Group will hold exclusive distribution rights across Southeast Asia (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines) for an initial three-year period • The collaboration aims to reduce risks to human workers while improving efficiency and sustainability through precise, technology-driven cleaning methods for high-rise buildings Commenting on the partnership, Mike Fu, Group CEO of YY Group, noted “This partnership with UnoMove underscores our vision of integrating robotics into the very fabric of facility management. By removing workers from one of the industry’s most dangerous tasks — working at heights — we are not only improving safety, but also enabling our teams to focus on higher-value inspection and supervisory roles. This is a step forward in building a safer, smarter, and more efficient future for the built environment.” Read the full press release here: https://lnkd.in/eJ6ddGzn. YY Group is led by a highly experienced management team including Mike Fu Xiaowei (“Mike”), Founder & CEO; Zhang Fan, Co-Founder & Director; Phua Zhi Yong (“Jason”), CFO; Rachel Xu, CHRO; and Teng Sin Ken, CIO. To learn more about YY Group Holding Limited, visit https://lnkd.in/eJ7tfezs. For investor inquiries, contact enquiries@yygroupholding.com or visit https://lnkd.in/e3kBiyXG.

Vycor Medical, Inc. Medical’s ViewSite™ Brain Access System (VBAS) is reshaping recovery trajectories in neurosurgery by shortening OR time and accelerating the transition from the OR to home. By minimizing retractor-related brain injury, VBAS enables shorter hospital stays, faster mobilization, and earlier discharge compared to traditional blade retractors. Shorter inpatient stays have a positive impact on quality of life for patients and reduce health care system costs. Vycor Medical, Inc. (OTCQB: VYCO) is a B2i Digital Venture Company. See the company’s complete profile at https://lnkd.in/eZxxWBVU. The device’s transparent tubular design distributes pressure evenly around brain tissue rather than concentrating force, a clear difference linked to fewer complications. In tumor surgery, VBAS has supported high rates of gross total resection, about 70% in published intraventricular series, with low rates of post-operative complications. Other studies confirm that tubular retractors like VBAS lower complication rates compared with older blade-style retractors. These clinical advantages have practical implications for patients and hospitals alike. Tissue disruption and blood loss are reduced, and post-operative pain relief requirements are lowered. Patients benefit from fewer complications, less swelling, and faster return to normal activity. Surgeons report improved visibility and maneuverability when working in deep or delicate regions. Hospitals gain from shorter lengths of stay that reduce costs and improve throughput. The ability to deliver both clinical and operational benefits is making VBAS a preferred tool in minimally invasive neurosurgery. Vycor operates two divisions: Vycor Medical (ViewSite™ Brain Access System for neurosurgery) and NovaVision (vision rehabilitation therapies for stroke/brain injury patients). A video replay of Vycor Medical’s recent presentation at the Life Sciences Virtual Investor Forum, featuring CEO Peter Zachariou and President David Cantor, is available here. Vycor is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance. More information is available at https://lnkd.in/eSATjP_X. For investor inquiries, please contact info@vycormedical.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased and currently owns shares of unrestricted VYCO stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of VYCO or any security, nor is it intended to offer any opinion on VYCO as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m.

Spartan Capital Securities, LLC and B2i Digital are pleased to announce that Gold Royalty Corp. (NYSE: GROY). (NYSE American: GROY) will be a presenting company at the upcoming Spartan Capital Investor Conference on November 3rd, 2025, in New York. The Spartan Capital Investor Conference 2025 is a B2i Digital Featured Conference. Now in its second year, the conference brings together public company executive teams, institutional investors, and thought leaders from across the U.S. capital markets for strategic networking and information exchange. Taking place at the Marriott Marquis Hotel in New York, this premier event will welcome 500+ institutional and high-net-worth investors and feature presentations from 60 public and private growth companies across technology, healthcare, consumer, and other high-opportunity sectors. Attendees can expect main-stage presentations, curated one-on-one meetings, and extensive networking opportunities that connect innovative companies with sophisticated capital. Investors can register to attend: https://lnkd.in/g8Y249nF. Event details and registration are available at https://lnkd.in/edsVSMsh. Gold Royalty Corp. is a gold-focused royalty company offering creative financing solutions to the metals and mining industry. Its mission is to invest in high-quality, sustainable, and responsible mining operations to build a diversified portfolio of precious metals royalty and streaming interests that generate superior long-term returns for our shareholders. Gold Royalty’s diversified portfolio currently consists primarily of net smelter return royalties on gold properties located in the Americas. The company is led by CEO, President and Chairman David Garofalo, FCPA, FCA, ICD.D with 30 years of natural resources leadership including former CEO of Goldcorp; CFO Andrew Gubbels, a founding executive of Aris Gold; Chief Development Officer John W. Griffith, former Head of Americas Metals & Mining Investment Banking at Bank of America; VP Capital Markets Jackie Przybylowski, former Managing Director at BMO Capital Markets; and Director of Technical Services Alastair Still with 25 years at major gold miners. B2i Digital is working closely with the Spartan Capital team, including John D. Lowry (CEO), Kim Monchik (CAO), Stephen Faucetta (Managing Director), and Julia Voss (Executive Assistant), to enhance each presenter’s reach through in-depth digital profiles and targeted outreach. Learn more about Gold Royalty Corp. at www.GoldRoyalty.com or contact Investor Relations at Info@GoldRoyalty.com.